



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 211/90, A61K 31/44</p>	A1	<p>(11) International Publication Number: WO 99/25688</p> <p>(43) International Publication Date: 27 May 1999 (27.05.99)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/DK98/00492</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 1299/97 14 November 1997 (14.11.97) DK</p> <p>(71) Applicant (for all designated States except US): A/S GEA FARMACEUTISK FABRIK [DK/DK]; Holger Danskes Vej 89, DK-2000 Frederiksberg (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KARUP, Gunnar, Leo [DK/DK]; Bremensgade 39, DK-2300 Copenhagen S (DK). PREIKSCHAT, Herbert, Fritz [DK/DK]; Langkærgårdsvej 22, DK-3460 Birkerød (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvej 7, DK-2650 Hvidovre (DK).</p> <p>(74) Agents: BAGGER-SØRENSEN, Birgitte et al.; Internationalt Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published With international search report.</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/DK98/00492</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 1299/97 14 November 1997 (14.11.97) DK</p> <p>(71) Applicant (for all designated States except US): A/S GEA FARMACEUTISK FABRIK [DK/DK]; Holger Danskes Vej 89, DK-2000 Frederiksberg (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KARUP, Gunnar, Leo [DK/DK]; Bremensgade 39, DK-2300 Copenhagen S (DK). PREIKSCHAT, Herbert, Fritz [DK/DK]; Langkærgårdsvej 22, DK-3460 Birkerød (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvej 7, DK-2650 Hvidovre (DK).</p> <p>(74) Agents: BAGGER-SØRENSEN, Birgitte et al.; Internationalt Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).</p>	<p>(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published With international search report.</p>
<p>(21) International Application Number: PCT/DK98/00492</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 1299/97 14 November 1997 (14.11.97) DK</p> <p>(71) Applicant (for all designated States except US): A/S GEA FARMACEUTISK FABRIK [DK/DK]; Holger Danskes Vej 89, DK-2000 Frederiksberg (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KARUP, Gunnar, Leo [DK/DK]; Bremensgade 39, DK-2300 Copenhagen S (DK). PREIKSCHAT, Herbert, Fritz [DK/DK]; Langkærgårdsvej 22, DK-3460 Birkerød (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvej 7, DK-2650 Hvidovre (DK).</p> <p>(74) Agents: BAGGER-SØRENSEN, Birgitte et al.; Internationalt Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).</p>	<p>(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published With international search report.</p>			
<p>(54) Title: PROCESS FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINES AND COMPOUNDS USED IN THIS PROCESS</p> <div style="text-align: center; margin: 20px 0;"> <p style="margin: 0;">(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;"> <p style="margin: 0;">(II)</p> </div> <div style="text-align: center;"> <p style="margin: 0;">(III)</p> </div> </div>				
<p>(57) Abstract</p> <p>A process for the preparation of 1,4-dihydropyridines of general formula (I) or acid addition salts thereof, comprising the steps of reacting an acetal of general formula (II) with R⁵ONH₂ or an acid addition salt thereof, so as to provide an oxime of general formula (III) in which formulae R¹ each, independently, represents H, Cl or CF₃, R² represents H, C₁-C₅ alkyl, C₃-C₆ cycloalkyl or aralkyl, n is 1 or 2, R³ and R⁴, which may be the same or different, represents C₁-C₅ alkyl, C₃-C₆ cycloalkyl, aralkyl or together represent -(CH₂)_m-, wherein m is 2 or 3, and R⁵ represents H, C₁-C₅ alkyl, C₃-C₆ cycloalkyl or aralkyl, and reducing the formed oxime of formula (III) so as to provide a 1,4-dihydropyridine of formula (I), and, if desired, converting a compound of formula (I) obtained as the free base into a pharmaceutically acceptable acid addition salt thereof or vice versa, and novel intermediates of the formulae (II) and (III) are described.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINES AND COMPOUNDS USED IN THIS PROCESS

The present invention relates to a process for the
5 preparation of certain 1,4-dihydropyridines having an
amino group attached to a substituent in the 2-position
of the 1,4-dihydropyridinium ring and pharmaceutically
acceptable acid addition salts thereof. In addition,
the invention relates to novel intermediates of use for
10 such purpose.

Compounds belonging to this class of 1,4-dihydro-
pyridines have shown activity as calcium-channel
blockers and have found utility as anti-ischaemic and
antihypertensive agents. Furthermore, compounds of this
15 class have been used in the treatment of Raynaud's
syndrome.

A particularly preferred compound of this class of
1,4-dihydropyridines is the compound, 2-(2-amino-
ethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-
20 pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl
ester, known under the generic name, amlodipine.

EP 0 089 167 B discloses certain 1,4-dihydropyri-
dines having an amino-containing group attached to the
2-position, i.a. amlodipine, and their preparation.

25 According to said patent, the 1,4-dihydropyridines
are prepared by removal of the amino-protecting group
from the corresponding amino-protected 1,4-dihydropyri-
dine or by reduction of the corresponding azido com-
pound into the amine. As well the amino-protected 1,4-
30 dihydropyridines as the azido compounds are prepared by
the well-known Hantzsch synthesis.

In Example 11 of the patent an overall yield of 1
%, only, is stated for the production of amlodipine
maleate starting with the reaction of 2-azido ethanol
35 with ethyl 4-chloroacetoacetate, whereas an overall

yield of 8.8 % is disclosed in a later publication by the inventors of EP 0 089 167 B, J. Med. Chem., (1986), 29, 1696 - 1702, see particularly pp. 1700 - 1701.

The overall yield for the alternative process has not been given in the patent and cannot be calculated on the basis of the information given therein. However, in part calculated on the basis of yields reported by others having reproduced the process, the overall yield seems to be in the order of 12 - 20 %, starting with the reaction of 2-phthalimido ethanol with ethyl 4-chloroacetoacetate and ending with removal of the protecting group and preparation of the maleate salt.

The present invention provides a process whereby the 1,4-dihydropyridines can be obtained in higher overall yield. Furthermore, the use of potentially explosive azide starting materials (see e.g. Chem. Ind., (1986), 10, 337) is avoided.

By the process according to the invention, the 1,4-dihydropyridines are prepared starting from an acetal intermediate which is reacted with hydroxylamine or a derivative thereof so as to produce an oxime intermediate which is reduced to provide the desired 1,4-dihydropyridine, optionally as a pharmaceutically acceptable acid addition salt thereof. Hereby the 1,4-dihydropyridines can be obtained in excellent yields. E.g. amlodipine, maleate has been obtained in a yield of about 62 % calculated on the acetal intermediate.

Furthermore, the acetal intermediate in itself can be obtained in excellent yield by the Hantzsch synthesis, as described in the following. Thus, the amlodipine acetal intermediate has been obtained in a yield of 42 % starting with the reaction of 2,2-diethoxyethanol with ethyl 4-chloroacetoacetate, and accordingly an overall yield of amlodipine, maleate of 29 %, calculated on the 2,2-diethoxyethanol, has been

obtained.

CA 2,188,071 A discloses a process for the preparation of 1,4-dihydropyridine derivatives, i.a. amlodipine, by reductive amination of the corresponding
5 aldehyde using ammonium acetate and sodium cyanohydride in a protic solvent such as methanol, or reaction of the aldehyde with hydroxylamine hydrochloride and base to give the corresponding oxime followed by reduction with ammonium formate in methanol in the presence of
10 palladium hydroxide on charcoal.

In CA 2,188,071 A it is stated that the dihydropyridine derivatives are formed in good yields employing easily available precursors, and that the overall yield is far greater than the prior art, i.e.
15 46 % for amlodipine. This yield, however, seems to be calculated on the compound, 4-(2-chlorophenyl)-2-(2,3-dihydroxypropoxymethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester, in CA 2,188,071 A designated IC. But as this compound already
20 includes the 1,4-dihydropyridine ring, an "overall" yield calculated on this basis cannot be compared to the overall yields indicated above.

A calculation on a comparable basis, i.e. based on the compound being reacted with ethyl 4-chloroacetate, viz. the compound 2,2-dimethyl-[1,3]dioxolane-
25 4,5-dimethanol, gives a yield of the aldehyde intermediate of about 15 % resulting in an overall yield of amlodipine of about 7 %, i.e. several times smaller than the overall yield of about 29 % which has been
30 obtained via the acetal intermediate used as starting material in the process according to the invention.

Also the yields, which have been obtained by conversion of the aldehyde intermediate into amlodipine by the process according to CA 2,188,071 A (about 48 %
35 by the reductive amination and about 43 % by conversion

via the oxime), are far below the yield of about 62 %, which has been obtained by the process according to the invention using the acetal intermediate as starting material, which yield even includes the preparation of the maleate salt.

Incidentally, CA 2,188,071 A discloses an acetal, viz. the compound 4-(2-chlorophenyl)-2-(2,2-dimethoxyethoxymethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester, as well as its preparation from 2,2-dimethoxyethanol and 2-(2-chloromethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester and its conversion into a bicyclic structure forming an oxazine ring with the pyridine nitrogen atom (cf. Examples 11 and 12). However, neither its conversion into the corresponding oxime nor its preparation by Hantzsch synthesis has been disclosed. There is no mentioning either of any possible use of the compound as intermediate in the preparation of amlodipine.

CA 2,188,071 A also includes a general formula XX for an acetal, but the formula includes two undefined substituents, R_{10} and R_{11} , and accordingly it cannot be considered an anticipating disclosure of any specific acetal. Furthermore, neither the conversion of the acetal into the corresponding oxime nor its preparation by Hantzsch synthesis has been disclosed. There is no mentioning either of any possible use of the acetal as intermediate in the preparation of amlodipine or any other 1,4-dihydropyridine having a substituent with an amino group in the 2-position of the 1,4-dihydropyridinium ring.

EP 225 175 A2 discloses a substantive number of 1,4-dihydropyridine derivatives and different processes for their preparation. Amlodipine is not among the disclosed derivatives. One of the disclosed processes is


a process for the preparation of a 1,4-dihydropyridine derivative, which like the compounds prepared by the process according to the invention, has a (2-aminoethoxy)methyl substituent in the 2-position, but
5 differs from said compounds in having a fluoromethyl substituent in the 6-position. The 1,4-dihydropyridine derivative is prepared by reduction of the corresponding oxime which in turn is prepared by reaction of the corresponding acetal with hydroxylamine.

10 However, EP 225 175 A2 does not mention anything about the acetal being obtained directly by the Hantzsch synthesis and even less the particular advantages obtainable thereby.

On the contrary, the acetal is prepared from the
15 corresponding bromomethyl substituted 1,4-dihydropyridine derivative obtained by reaction of the corresponding methyl substituted 1,4-dihydropyridine derivative with pyridinium perbromide, a process which would be unsuitable for the preparation of the acetal used in
20 the process according to the present invention due to side reactions.

Thus, it can be concluded, that the use of the acetal intermediate in the preparation of the particular 1,4-dihydropyridines being prepared by the process
25 according to the present invention presents substantive advantages over the prior art and cannot be considered obvious in view thereof.

Accordingly, the invention provides an inventive process for the preparation of 1,4-dihydropyridines of
30 the general formula I



5

wherein

R^1 each, independently, represents H, Cl or CF_3 ,


R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
10 aralkyl, and

n is 1 or 2,

or acid addition salts thereof,

comprising the steps of reacting an acetal of the
general formula II

15



20

wherein

R^1 , R^2 and n have the same meanings as defined
above, and

R^3 and R^4 , which may be the same or different,
25 represent C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, aralkyl or
together represent $-(CH_2)_m-$, wherein

m is 2 or 3,

with

30




or an acid addition salt thereof, wherein

R^5 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
aralkyl,

so as to provide an oxime of the general formula

III

5



III

wherein

10 R^1 , R^2 , R^5 and n have the same meanings as defined above, and

reducing the formed oxime of formula III so as to provide a 1,4-dihydropyridine of formula I, and, if desired, converting a compound of formula I obtained as
15 the free base into a pharmaceutically acceptable acid addition salt thereof or vice versa.

The reaction of the acetal of formula II with R^5ONH_2 or an acid addition salt thereof to give the oxime of formula III is carried out in an appropriate
20 solvent, such as an alcoholic solvent comprising a lower alkanol, such as methanol, ethanol or isopropanol, e.g. in admixture with water. In a presently preferred embodiment an aqueous solution of R^5ONH_2 , hydrochloride is combined with a solution of the acetal
25 in methanol, and the mixture is heated to reflux for a suitable period, such as 2 - 8 hours, normally around 4 hours.

The reduction of the oxime of formula III into the desired 1,4-dihydropyridine of formula I is carried out
30 using a suitable reduction agent selected from the numerous reduction agents being known for the reduction of oximes into amines, see e.g. the surveys given in R. C. Larock, "Comprehensive Organic Transformations", VCH Publishers, (1989). p. 424, Houben-Weyl: "Methoden der
35 Organischen Chemie", Vol. E16d, Part 2, (1992), pp. 884

- 893, and Houben-Weyl: "Methoden der Organischen Chemie", Vol. XI/1, (1957), pp. 495 -504.

According to a particular embodiment of the invention, the reduction is carried out by catalytical hydrogenation, preferably using a nobel metal catalyst, such as platinum or palladium, or a Raney nickel catalyst. The reduction is preferably carried out under acidic conditions.

In a presently preferred embodiment, the reduction is carried out by catalytical hydrogenation in acetic acid using palladium-on-carbon as a catalyst.


According to another, although less preferred embodiment of the invention, the reduction is carried out using sodium borohydride/nickel chloride hydrate as reduction agent.

As other examples of catalysts, which may be of use for the present purpose, the following can be mentioned: sodium borohydride in combination with other compounds, such as titanium tetrachloride or molybdenum trichloride; lithium aluminum hydride or zinc powder.

A compound of formula I obtained as the free base may, if desired, be converted into a pharmaceutically acceptable acid addition salt thereof or vice versa. The hydrochloride, hydrobromide, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, besylate, lactate, tartrate, citrate and gluconate salts are examples of such pharmaceutically acceptable acid addition salts. The maleate and the besylate salts are particularly preferred.

With the exception of the compound 4-(2-chlorophenyl)-2-(2,2-dimethoxy-ethoxymethyl)-1,4-dihydro-6-methyl-3,5-pyridine-dicarboxylic acid 3-ethyl 5-methyl ester, the acetals of formula II are novel compounds and as such represent a particular aspect of the invention.

A specific group of acetals according to the invention, are the compounds of the general formula II



wherein

10 R^1 each, independently, represents H, Cl or CF_3 ,
 R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or aralkyl,

R^3 and R^4 , which may be the same or different, represent C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, aralkyl or
 15 together represent $-(CH_2)_m-$, wherein

m is 2 or 3, and

n is 1 or 2,

with the proviso that when R^2 is H, and no R^1 is CF_3 , then R^3 and R^4 are other than methyl.

20 A preferred group of acetals of the general formula II is represented by the compounds wherein n is 1, R^1 is chloro in the 2-position of the phenyl ring, R^2 is H, and R^3 and R^4 , which may be the same or different, represent C_2 - C_5 alkyl.


25 Particularly preferred is the compound 4-(2-chlorophenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester.

The acetals of formula II can be obtained directly
 30 by the Hantzsch synthesis and have been obtained in excellent yield by this synthesis.

Accordingly, in a preferred embodiment of the process according to the invention the acetal of formula II is obtained by a Hantzsch synthesis carried
 35 out using a compound containing a group of the formula

10

5




wherein

R^3 and R^4 have the same meanings as defined above,
 10 as one of the reactants in the Hantzsch condensation.

In principle the Hantzsch synthesis is carried out
 by reacting an aldehyde with a β -keto ester and an
 aminocrotonic acid ester as illustrated in the follow-
 ing Scheme 1:

15




Scheme 1

However, as is known in the art, various modifica-
 35 tions of the Hantzsch synthesis are possible.

11


Instead of performing the reaction in one step as illustrated above, the synthesis can be carried out using preformed intermediates, e.g. as illustrated in the following Schemes 2, 3 and 4:

5




Scheme 2

15



Scheme 3

25



Scheme 4


As will be appreciated by a person skilled in the art the above schemes are only examples and other modifications of the Hantzsch synthesis can be made without deviating from the scope and spirit of the invention.

In a further preferred embodiment of the process according to the invention, the Hantzsch synthesis, or at least one step thereof, is carried out in a solvent being capable of forming an azeotrope with water, particularly toluene, benzene or xylene. Hereby, water of reaction can be removed as an azeotrope with the solvent during the reaction.

Some of the oximes of formula III are novel compounds and as such represent a particular aspect of the invention.

The only oximes of formula III being specifically disclosed in CA 2,188,071 A are the compound, 4-(2-chloro-phenyl)-2-(2-hydroxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester and the corresponding 2-methoxyimino compound.

Accordingly, the invention also relates to the oximes of the general formula III



wherein

R^1 each, independently, represent H, Cl or CF_3 ,

R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
10 aralkyl,

R^5 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
aralkyl, and

n is 1 or 2,

with the exception of the compounds 4-(2-chloro-
15 phenyl)-2-(2-hydroxyimino-ethoxymethyl)-6-methyl-1,4-
dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-
methyl ester and 4-(2-chloro-phenyl)-2-(2-methoxyimino-
ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicar-
boxylic acid 3-ethyl ester 5-methyl ester.

20 A particular group of compounds of formula III
according to the invention are the compounds wherein

R^1 each, independently, represent H, Cl or CF_3 ,

R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
aralkyl,

25 R^5 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
aralkyl, and

n is 1 or 2,

with the proviso that when R^2 is H and no R^1 is CF_3 ,
then R^5 is C_3 - C_6 cycloalkyl or aralkyl.

30 In the present specification and claims, the
definition C_1 - C_5 alkyl includes linear and branched
alkyl groups like methyl, ethyl, propyl, incl. n-propyl
and i-propyl, butyl, incl. n-butyl, sec.-butyl and
tert.-butyl, and pentyl, incl. n-pentyl and tert.-
35 pentyl. The definition C_3 - C_6 cycloalkyl includes

cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and the definition aralkyl includes groups having a phenyl or naphthyl group, particularly a phenyl group, as the aryl moiety and a C₁-C₅ alkyl group as defined above as the alkyl moiety, the benzyl group being a particularly preferred aralkyl group.

The invention will now be further illustrated by specific examples which, however, should not be regarded as any limitation of the scope of the invention.

EXAMPLES.

Preparation of starting materials.

15

Example A. 4-(2,2-Diethoxy-ethoxy)-3-oxo-butyric acid ethyl ester (1).

To a stirred suspension of 58,8 g 60 % (1.47 mol) sodium hydride in 600 ml anhydrous tetrahydrofuran, a solution of 94 g (0.7 mol) 2,2-diethoxy-ethanol in 160 ml tetrahydrofuran was added dropwise, so that the temperature was kept below 40 °C. After completion of the addition, the reaction mixture was stirred for further 30 minutes. Then 115 g (0.7 mol) ethyl 4-chloroacetoacetate in 500 ml anhydrous tetrahydrofuran was added dropwise within 3 hours, so that the temperature was kept between 10 °C and 40 °C, preferentially at about 20 °C. The mixture was stirred overnight at room temperature. Then 90 ml ethanol was added dropwise, and the mixture was poured into 900 g of ice after which pH was adjusted to 6 with hydrochloric acid. The organic phase was separated and dried over MgSO₄. The tetrahydrofuran was evaporated off and the product was separated from the oily layer in a separ-

15

ation funnel. Then the product was dissolved in toluene and purified by filtration through a short column of silica. The toluene was evaporated off, leaving the product as a light yellow oil. The product was purified
5 by distillation in vacuo.

yield: 130.9 g = 71.4 %

bp. = 112-114 °C at 0.2 mm Hg

10

Elemental analysis:

Calculated: C 54.9% H 8.5%

Found: C 54.48% H 8.7%

15 IR: 2986 cm⁻¹; 1726 cm⁻¹; 1748 cm⁻¹; 1119 cm⁻¹; 1067 cm⁻¹
(Between KBr plates)

NMR: 250 MHz ¹H-NMR (CDCl₃) (δ ppm):

4.646 (t, H, CH); 4.286 (s, 2H, CH₂); 4.224 (s, 2H,
20 CH₂); 3.708 (q, 2H, CH₂); 3.568 (q, 2H, CH₂); 3.556 (d,
2H, CH₂); 1.30 (t, 3H, CH₃); 1.21 (m, 6H, CH₃).

Example B. 3-(2-chloro-phenyl)-2-[2-(2,2-diethoxy-
25 xy-ethoxy)-acetyl]-acrylic acid ethyl ester (cis and
trans isomer) (2).

A solution of 53 g (0.38 mol) 2-chlorobenzaldehyde, 98 g (0.38 mol) 4-(2,2-diethoxy-ethoxy)-3-oxo-
30 butyric acid ethyl ester (1) and 6 ml piperidine in
1600 ml toluene was refluxed in a Dean-Stark water
separator for four hours until 6.2 ml of water had been
separated (theoretical amount = 6.5 ml). The reaction
mixture was cooled to room temperature and washed twice
35 with 200 ml of water, then with 500 ml of a saturated

16

solution of sodium bisulphite and finally with 200 ml of water. The mixture was dried over MgSO_4 and the toluene was evaporated off to give the product as a dark red oil.

5

yield: 99.3 g = 67.9 %

Elemental analysis:

Calculated: C 59.3% H 6.5% Cl 9.2%

10 Found: C 59.41% H 7.11% Cl 9.2%

IR: 2977 cm^{-1} ; 2931 cm^{-1} ; 1725 cm^{-1} ; 1617 cm^{-1} ; 1443 cm^{-1} ; 1375 cm^{-1} ; 1253 cm^{-1} ; 1121 cm^{-1} ; 1057 cm^{-1} ; 760 cm^{-1} ; (Between KBr plates)

15

NMR: 500 Mhz ^1H -NMR (CDCl_3) (δ ppm):

Mixture of geometric isomers

8.07, 7.97 (2 s cis,trans, 1H, CH); 7.48-7.12 (m, 4H, ArH); 4.656, 4.576 (2 t cis,trans, 2H, CH); 4.3 (d.d., 20 2H, CH₂); 4.154 (m, 2H, CH₂); 3.682 (m, 2H, CH₂); 3.53 (m, 4H, CH₂); 1.324 (t, 3H, CH₃); 1.184 (t, 6H, CH₃).

Example C. 3-amino-4-(2,2-diethoxy-ethoxy)but-2-enoic acid ethyl ester (3).

A mixture of 26.2 g (0.1 mol) 4-(2,2-diethoxy-ethoxy)-3-oxo-butyric acid ethyl ester (1) and 8.47 g (0.11 mol) of ammonium acetate in 75 ml of ethanol was 30 refluxed for 60 minutes. The ethanol was evaporated off and the resulting crude 3-amino-4-(2,2-diethoxy-ethoxy)but-2-enoic acid ethyl ester was dissolved in 100 ml of toluene and washed twice with 75 ml of water. The organic phase was evaporated off and the crude product 35 was distilled in vacuo giving the pure compound as a

17

colourless liquid.

bp. = 130-131 °C at 0.3 mm Hg

5 yield: 23.0 g = 88 %

Elemental analysis:

Calculated:	C 55.2%	H 8.9%	Cl 5.4%
Found:	C 55.91%	H 8.9%	Cl 5.4%

10

IR: 3445 cm⁻¹; 3336 cm⁻¹; 2976 cm⁻¹; 2930 cm⁻¹; 1669 cm⁻¹; 1622 cm⁻¹; 1564 cm⁻¹; 1445 cm⁻¹; 1367 cm⁻¹; 1286 cm⁻¹; 1162 cm⁻¹; 1116 cm⁻¹; 1065 cm⁻¹; 788 cm⁻¹.

15 NMR: 250 Mhz ¹H-NMR (CDCl₃) (δ ppm): (Imine tautomer)
4.632 (t, H, CH); 4.512 (s br., H, NH); 4.112 (q, 2H, CH₂); 4.102 (s, 2H, CH₂); 3.705 (q, 2H, CH₂); 3.576 (q, 2H, CH₂); 3.508 (d, 2H, CH₂); 1.266 (m, 9H, CH₃)

20 FAB-MS: 261 [MH⁺], 216, 170

Example D1. 4-(2-chloro-phenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester (4).

A mixture of 83 g (0.218 mol) 3-(2-chloro-phenyl)-2-[2-(2,2-diethoxy-ethoxy)-acetyl]-acrylic acid ethyl ester (cis and trans isomer) (2) and 25 g (0.218 mol) of methyl-3-aminocrotonate in 800 ml toluene was refluxed in a Dean-Stark water separator for 30 hours. Toluene was evaporated off to give 104 g of the crude product (70 % purity, HPLC) as a dark red oil. The crude product was chromatographed on silica with 35 toluene/ethylacetate 20:1 as eluent. Appropriate

fractions were combined to give the product (95-98 % purity, HPLC) as a light yellow glass, which crystallized after several days of standing.

5 yield: 56.6 g = 53.9 %

mp. 64-67 °C

Elemental analysis:

10 Calculated:	C 59.8%	H 6.7%	N 2.9%	Cl 7.4%
Found:	C 59.59%	H 7.14%	N 2.76%	Cl 7.5%

IR: 3349 cm^{-1} ; 2977 cm^{-1} ; 2931 cm^{-1} ; 1692 cm^{-1} ; 1646 cm^{-1} ;
1611 cm^{-1} ; 1482 cm^{-1} ; 1208 cm^{-1} ; 1163 cm^{-1} ; 1100 cm^{-1} ;
15 1060 cm^{-1} ; 757 cm^{-1} ;
(KBr)

NMR: 500 MHz ^1H -NMR (CDCl_3) (δ ppm):

7.41 (br. s, 1H, NH); 7.08-7.39 (m, 4H, ArH); 5.42 (s,
20 1H, CH); 4.774 (d.d., 2H, CH₂); 4.684 (t, 1H, CH); 4.04
(q, 2H, CH₂); 3.74 (m, 2H, CH₂); 3.61 (s, 3H, CH₃);
3.58 (s, 4H, CH₂); 2.35 (s, 3H, CH₃); 1.26 (d. t, 6H,
CH₃); 1.176 (d. t, 3H, CH₃).

25 FAB-MS: 482 [MH^+], 481 [M^+], 370 [$\text{M}^+ - \text{C}_6\text{H}_4\text{Cl}$]

Example D2. 4-(2-chloro-phenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicar-
30 boxylic acid 3-ethyl ester 5-methyl ester (4).

26,13 g (0,1 mol) 3-amino-4-(2,2-diethoxy-ethoxy)-but-2-enoic acid ethyl ester (3) and 23.90 g (0.1 mol) 2-acetyl-3-(2-chloro-phenyl)-acrylic acid methyl
35 ester was dissolved in 200 ml toluene and refluxed in

a Dean-Stark water separator for 26 hours. Toluene was evaporated off to give the crude product (88% purity, HPLC) as a yellow oil, which became semicrystalline overnight. The semicrystalline product was stirred
5 vigorously with hexane for a few hours. The resulting crystalline product was filtered off and dried to give 28 g of the pure product. The hexane was evaporated off and the residue was chromatographed on silica with toluene/ethylacetate 20:1 as eluent. Appropriate
10 fractions were combined to give the product (95-98% purity, HPLC) as a light yellow glass, which was stirred with hexane for a few hours. This gave further 8,30 g of pure product after filtering and drying.

15 Combined yield: 36.3 g = 75.3 %

mp. 64-67 °C

Elemental analysis:

20 Calculated: C 59.8% H 6.7% N 2.9% Cl 7.4%
Found: C 59.59% H 7.14% N 2.76% Cl 7.5%

IR: 3349 cm^{-1} ; 2977 cm^{-1} ; 2931 cm^{-1} ; 1692 cm^{-1} ; 1646 cm^{-1} ;
1611 cm^{-1} ; 1482 cm^{-1} ; 1208 cm^{-1} ; 1163 cm^{-1} ; 1100 cm^{-1} ;
25 1060 cm^{-1} ; 757 cm^{-1} ;
(KBr)

NMR: 500 MHz ^1H -NMR (CDCl_3) (δ ppm):

7.41 (br. s, 1H, NH); 7.08-7.39 (m, 4H, ArH) 5.42 (s,
30 1H, CH); 4.774 (d.d., 2H, CH₂); 4.684 (t, 1H, CH); 4.04
(q, 2H, CH₂); 3.74 (m, 2H, CH₂); 3.61 (s, 3H, CH₃);
3.58 (s, 4H, CH₂); 2.35 (s, 3H, CH₃); 1.26 (d. t, 6H,
CH₃); 1.176 (d. t, 3H, CH₃).

35 FAB-MS: 482 [MH^+], 481 [M^+], 370 [$\text{M}^+ - \text{C}_6\text{H}_4\text{Cl}$]

Example E. 1-Benzyl-4-(2-chloro-phenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester (7).

5 A mixture of 9.6 g (0.025 mol) 3-(2-chloro-phenyl)-2-[2-(2,2-diethoxy-ethoxy)-acetyl]-acrylic acid ethyl ester (cis and trans isomer) (2) and 5.12 g (0.025 mol) of methyl-3-benzylaminocrotonate in 250 ml toluene was refluxed in a Dean-Stark water separator
10 for 48 hours. The toluene was evaporated off to give 14 g of the crude product (68 % purity) as a dark red oil. The crude product was chromatographed on silica with chloroform as eluent.

Appropriate fractions were combined to give the
15 product (95-98% purity) as a light brown oil.

yield: 7.8 g = 55 %

Elemental analysis:

20 Calculated:	C 65.1%	H 6.7%	N 2.4%	Cl 6.2%
Found:	C 64.38%	H 7.06%	N 2.34%	Cl 6.4%

FAB-MS: 572 [MH⁺], 571 [M⁺]

25 Example F. 2,2-Diethoxy-ethanol.

302,6 g (8 mol) of sodium borohydride was added to 2 l of 1,2-dimethoxyethane (monoglyme) with stirring, after which 704,8 g (4 mol) ethyl diethoxyacetate dissolved in 4 l of ethanol was added dropwise within 4
30 hours so that the temperature was kept below 50 °C. The mixture was then heated to reflux for 3 hours. Then 2 l of ethanol was distilled off, and 4 l of water was added dropwise while the remaining ethanol and then the
35 1,2-dimethoxyethane was removed by distillation. During

the water addition an abundant precipitate was formed which dissolved towards the end of the addition.

The mixture was cooled on an icebath and 600 g of potassium carbonate was dissolved therein while stirring. The mixture was extracted with 2 l of diethyl ether and dried with MgSO_4 . The diethyl ether was evaporated off and the crude product was distilled in vacuo at 75-76 °C (15 mm Hg).

10 Yield = 475.8 g = 88.7 %

Elemental analysis:

Calculated: C 53.7% H 10.5%

Found: C 53.11% H 10.57%

15

IR: 3441 cm^{-1} ; 2976 cm^{-1} ; 2931 cm^{-1} ; 2883 cm^{-1} ; 1445 cm^{-1}
1374 cm^{-1} ; 1345 cm^{-1} ; 1235 cm^{-1} ; 1134 cm^{-1} ; 1073 cm^{-1}
(Between KBr plates)

20

Examples illustrating the process according to the invention.

25 Example 1. 2-(2-aminoethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester, maleate; Amlodipine maleate.

30 A. 4-(2-chloro-phenyl)-2-(2-hydroxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester (5).

2,4 g (5 mmol) 4-(2-chloro-phenyl)-2-(2,2-di-
35 ethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-

-dicarboxylic acid 3-ethyl ester 5-methyl ester (4) was dissolved in 75 ml methanol. 20 ml of 0,5 M hydroxylamine hydrochloride in water was added, and the mixture was refluxed for four hours. The methanol was evaporated off, and 75 ml of chloroform was added. The organic phase was washed twice with 75 ml of water and then dried with magnesium sulphate. The chloroform was evaporated off leaving the crude product which was stirred for a few hours with 40 ml of petroleum ether bp. 60-80 °C and 10 - 15 ml of toluene. The precipitate was filtered off and then washed with petroleum ether, giving the product as a white powder.

yield: 1.40 g = 66.2 %

15

mp. 159-160 °C

Elemental analysis:

Calculated: C 56.8% H 5.5% N 6.6% Cl 8.4

20 Found: C 56.8% H 5.67% N 6.4% Cl 8.5%

IR: 3405 cm⁻¹; 2982 cm⁻¹; 2947 cm⁻¹; 1694 cm⁻¹; 1607 cm⁻¹; 1481 cm⁻¹; 1310 cm⁻¹; 1284 cm⁻¹; 1211 cm⁻¹; 1101 cm⁻¹; 758 cm⁻¹;

25 (KBr)

FAB-MS: 423 [MH⁺], 422 [M⁺], 311 [M⁺-C₆H₄Cl]

NMR: 500 MHz 1H-NMR (CDCl₃) (δ ppm):

30 6.96-7.57 (m, 6H, ArH, CH, NH) 5.414 (s, 1H, CH); 4.774 (d.d., 2H, CH₂); 4.462 (d, 1H, OH); 4.232 (d. d, 2H, CH₂); 4.048 (m, 2H, CH₂); 3.618 (s, 3H, CH₃); 2.34 (s, 3H, CH₃); 1.18 (t, 3H, CH₃).

B. 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester, maleate; Amlodipine maleate.

5

1.00 g (2.4 mmol) 4-(2-chloro-phenyl)-2-(2-hydroxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester (5) was dissolved in 20 ml glacial acetic acid and
10 hydrogenated for four hours at atmospheric pressure and room temperature using 0.062 g palladium 10% on carbon as catalyst. The catalyst was filtered off after which the acetic acid was evaporated off. The residue was dissolved in ether and washed successively with 10%
15 sodium bicarbonate solution and water. After drying with MgSO_4 the ether was evaporated off and the residue was dissolved in a small volume of ethanol. To the resulting solution 0.28 g (2.4 mmol) of maleic acid was added with cooling. The maleate salt precipitated after
20 a while and was then filtered off and washed with diethyl ether and dried in vacuo, giving 0.9 g of the product as a fine white powder. By addition of a small amount of ether to the mother liquor further 270 mg of product was obtained.

25

Combined yield: 1.17 g = 92.9 %

mp. 170-172 °C

30 Elemental analysis:

Calculated: C 54.9% H 5.6% N 5.3% Cl 6.8%

Found: C 53.86% H 5.6% N 5.11% Cl 6.9%

IR: 3392 cm^{-1} ; 2946 cm^{-1} ; 1688 cm^{-1} ; 1648 cm^{-1} ; 1603 cm^{-1} ;
35 1479 cm^{-1} ; 1283 cm^{-1} ; 1206 cm^{-1} ; 1100 cm^{-1} ; 759 cm^{-1} ;

(KBr)

FAB-MS: 409 [MH⁺], 408 [M⁺], 297 [M⁺-C₆H₄Cl]

5 NMR: 500 MHz 1H-NMR (D₆-DMSO) (δ ppm):
8.37 (s, 1H, NH); 7.87 (br. s, 3H, NH); 7.10-7.35 (m,
4H, ArH); 6.06 (s, 2H, CH); 5.31 (s, 1H, CH); 4.66 (d.
d., 2H, CH₂); 3.97 (q, 2H, CH₂); 3.66 (t, 2H, CH₂);
3.50 (s, 3H, CH₃); 3.09 (t, 2H, CH₃); 2.3 (t, 3H, CH₃);
10 1.12 (t, 3H, CH₃).

Example 2. 2-(2-aminoethoxymethyl)-4-(2-chloro-
phenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic
15 acid 3-ethyl ester 5-methyl ester, maleate; Amlodipine
maleate.

0.5 g (1.2 mmol) 4-(2-chloro-phenyl)-2-(2-hy-
droxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-
20 -3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester (5)
and 0.56 g (2.4 mmol) nickel chloride hydrate was
dissolved in 35 ml methanol and cooled to -30 °C. 0.454
g (0.012 mol) sodium borohydride was added in small
portions over 30 minutes whereafter the mixture was
25 stirred for 1 hour at room temperature. The mixture was
evaporated to dryness and 20 ml of 6N hydrochloric acid
was added with stirring. The mixture was filtered and
then made alkaline with conc. ammonium hydroxide (pH >
8.5). The filtrate was extracted twice with dichloro-
30 methane, and then dried with MgSO₄. The organic phase
was evaporated to give 0.274 g (56.7 %) of the crude
base. The product was dissolved in a small amount of
ethanol. To the resulting solution 0.08 g (0.7 mmol)
maleic acid was added with cooling. After a while the
35 maleate salt precipitated and was then filtered off and

25

washed with diethyl ether and dried in vacuo, giving the product as a fine white powder.

yield: 0.21 g = 33.4 %

5

mp. 170-172 °C

Elemental analysis:

Calculated: C 54.9% H 5.6% N 5.3% Cl 6.8%

10 Found: C 54.94% H 5.65% N 5.23% Cl 7.05%

IR: 3392 cm⁻¹; 2946 cm⁻¹; 1688 cm⁻¹; 1648 cm⁻¹; 1603 cm⁻¹;
1479 cm⁻¹; 1283 cm⁻¹; 1206 cm⁻¹; 1100 cm⁻¹; 759 cm⁻¹;
(KBr)

15

FAB-MS: 409 [MH⁺], 408 [M⁺], 297 [M⁺-C₆H₄Cl]

Example 3. 4-(2-chloro-phenyl)-2-(2-benzyloxy-
20 imino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-
-dicarboxylic acid 3-ethyl ester 5-methyl ester (8).

2,4 g (5 mmol) 4-(2-chloro-phenyl)-2-(2,2-diethoxy-ethoxymethyl)-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic
25 acid 3-ethyl ester 5-methyl ester (4) was dissolved in 75 ml methanol. 20 ml of 0,5 M O-benzylhydroxylamine hydrochloride in water was added, and the mixture was refluxed for four hours. The methanol was evaporated off, and 75 ml of dichloromethane was added. The
30 organic phase was washed twice with 75 ml of water and then dried with magnesium sulphate. Dichloromethane was evaporated off leaving the product as an oil. The crude product was chromatographed on silica with chloroform as eluent. Appropriate fractions were combined to give
35 the product as a brown oil.

yield: 2.3 g = 90 %

Elemental analysis:


Calculated:	C 63.2%	H 5.7%	N 5.5%	Cl 6.9%
5 Found:	C 62.5%	H 5.8%	N 5.2	Cl 6.6%

FAB-MS: 513 [MH⁺], 512 [M⁺], 401 [M⁺-C₆H₄Cl]

- 10 In the preceding the invention has been described by means of specific examples of preferred embodiments. However, it will be appreciated by a person skilled in the art that various modifications can be made without deviating from the spirit and scope of the invention.

P A T E N T C L A I M S

1. A process for the preparation of 1,4-dihydropyridines of the general formula I



10 wherein


R^1 each, independently, represents H, Cl or CF_3 ,

R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or aralkyl, and

n is 1 or 2,

15 or acid addition salts thereof,

comprising the steps of reacting an acetal of the general formula II



wherein

25 R^1 , R^2 and n have the same meanings as defined above, and

R^3 and R^4 , which may be the same or different, represent C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, aralkyl or together represent $-(CH_2)_m-$, wherein

30 m is 2 or 3,

with




35 or an acid addition salt thereof, wherein

R^5 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or aralkyl,

so as to provide an oxime of the general formula

III

5



10

wherein

R^1 , R^2 , R^5 and n have the same meanings as defined above, and

reducing the formed oxime of formula III so as to provide a 1,4-dihydropyridine of formula I, and, if desired, converting a compound of formula I obtained as the free base into a pharmaceutically acceptable acid addition salt thereof or vice versa.

20 2. A process according to claim 1, wherein the reduction of the oxime of formula III is carried out by catalytical hydrogenation.

3. A process according to claim 2, wherein the catalytical hydrogenation is carried out using a platinum, palladium or Raney nickel catalyst.

4. A process according to any of claims 1 - 3, wherein the reduction is carried out under acidic conditions.


5. A process according to any of claims 1 - 4, wherein the reduction is carried out by catalytical hydrogenation in acetic acid using palladium-on-carbon as a catalyst.

6. A process according to claim 1, wherein the reduction of the oxime of formula III is carried out using sodium borohydride/nickel chloride hydrate as reduction agent.

5

7. A process according to any of claims 1 - 6, wherein the acetal of formula II is obtained by a Hantzsch synthesis carried out using a compound containing a group of the formula

10



15

wherein

R^3 and R^4 have the same meanings as defined above, as one of the reactants in the Hantzsch condensation.

20

8. A process according to claim 7, wherein the Hantzsch synthesis, or at least one step thereof, is carried out in a solvent being capable of forming an azeotrope with water, particularly toluene, benzene or xylene.

25


9. A process according to claim 7 or 8, wherein the Hantzsch synthesis, or at least one step thereof, is carried out under azeotropic removal of water of reaction.

30

10. A process according to any of claims 1 - 9, wherein n is 1, R^1 is chloro in the 2-position of the phenyl ring, and R^2 is H.

35

11. An acetal of the general formula II



wherein

R^1 each, independently, represents H, Cl or CF_3 ,

10 R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or aralkyl,

R^3 and R^4 , which may be the same or different, represent C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, aralkyl or together represent $-(CH_2)_m-$, wherein


15 m is 2 or 3, and

n is 1 or 2,

with the exception of the compound 4-(2-chlorophenyl)-2-(2,2-dimethoxy-ethoxymethyl)-1,4-dihydro-6-methyl-3,5-pyridine-dicarboxylic acid 3-ethyl 5-methyl ester.

20

12. An acetal of the general formula II



wherein

R^1 each, independently, represents H, Cl or CF_3 ,


30 R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or aralkyl,

R^3 and R^4 , which may be the same or different, represent C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl, aralkyl or together represent $-(CH_2)_m-$, wherein

35 m is 2 or 3, and

n is 1 or 2,
with the proviso that when R^2 is H, and no R^1 is CF_3 ,
then R^3 and R^4 are other than methyl.

13. An acetal of the general formula II




wherein

n is 1,
 R^1 is chloro in the 2-position of the phenyl ring,
15 R^2 is H, and
 R^3 and R^4 , which may be the same or different,
represent C_2 - C_5 alkyl.

14. The compound 4-(2-chlorophenyl)-2-(2,2-di-
20 ethoxy-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-
dicarboxylic acid 3-ethyl ester 5-methyl ester.

15. An oxime of the general formula III




30 wherein

R^1 each, independently, represent H, Cl or CF_3 ,
 R^2 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
aralkyl,
 R^5 represents H, C_1 - C_5 alkyl, C_3 - C_6 cycloalkyl or
35 aralkyl, and

n is 1 or 2,
 with the exception of the compounds 4-(2-chloro-phenyl)-2-(2-hydroxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester and 4-(2-chloro-phenyl)-2-(2-methoxyimino-ethoxymethyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester.

16. An oxime of the general formula III

10



15

wherein

R¹ each, independently, represent H, Cl or CF₃,

R² represents H, C₁-C₅ alkyl, C₃-C₆ cycloalkyl or aralkyl,

20 R⁵ represents H, C₁-C₅ alkyl, C₃-C₆ cycloalkyl or aralkyl, and

n is 1 or 2,

with the proviso that when R² is H and no R¹ is CF₃, then R⁵ is C₃-C₆ cycloalkyl or aralkyl.

25

INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/DK 98/00492

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>J.E. ARROWSMITH ET AL.: "Long acting dihydropyridine calcium antagonists" JOURNAL OF MEDICINAL CHEMISTRY., vol. 29, no. 9, 1986, pages 1696-1702, XP002070765 WASHINGTON US cited in the application -----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/DK 98/00492

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
CA 2188071	A	02-05-1997	NZ 280378 A	27-04-1998
			US 5723618 A	03-03-1998
EP 0225175	A	10-06-1987	JP 62187453 A	15-08-1987
EP 0089167	A	21-09-1983	AT 22884 T	15-11-1986
			AU 540769 B	06-12-1984
			AU 1235183 A	22-09-1983
			BG 60658 B	30-11-1995
			CA 1253865 A	09-05-1989
			CS 8301499 A	13-06-1985
			CS 8401592 A	13-06-1985
			CS 240998 B	13-03-1986
			CS 9104188 A	16-09-1992
			DD 209622 A	16-05-1984
			DD 218887 A	20-02-1985
			DK 81383 A,B,	12-09-1983
			EG 16987 A	30-03-1991
			FI 830789 A,B	12-09-1983
			GR 77429 A	14-09-1984
			HK 16288 A	11-03-1988
			HR 930369 B	29-02-1996
			HR 930370 B	29-02-1996
			IE 54667 B	03-01-1990
			IE 54765 B	31-01-1990
			JP 1401088 C	28-09-1987
			JP 58167569 A	03-10-1983
			JP 62006703 B	13-02-1987
			KE 3778 A	27-11-1987
			LU 88332 A	04-05-1994
			LV 5236 A	10-10-1993
			LV 5235 A	10-10-1993
			PT 76370 B	27-03-1986
			SI 8310586 A	29-02-1996
			SI 8511419 A	31-10-1996
			SU 1238730 A	15-06-1986
			SU 1227110 A	23-04-1986
			US 4572909 A	25-02-1986
			ZA 8301651 A	28-12-1983